Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCLs). Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.
Thiopurines are effective anti-inflammatory, anticancer and immunosuppresive drugs. However, azathioprine is also a carcinogen. So, how do thiopurines exert their therapeutic and carcinogenic effects?
High-dimensional genomic and proteomic data are now commonplace in cancer research. This Review aims to help biologists understand the properties of high-dimensional data spaces and how these affect our ability to derive meaningful information from the data.
This Perspective considers the differences between the hypoxia-inducible factor (HIF)–MYC transcriptional network that operates under normal homeostatic conditions and the network that operates in a tumorigenic milieu.
The authors propose a model of carcinogenesis that identifies microenvironmental barriers that have to be overcome before cancer can become invasive. These adaptations lead to the hallmarks of the malignant phenotype.
In the past 10 years, much has been learned about the biology of the inhibitor of apoptosis protein survivin and its expression and roles in cancer. Does survivin function as a nodal protein in cancer networks, and does this make it a promising therapeutic target?
